Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors
March 28 2016 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
Geoffrey Parker has been appointed to the Sunesis Board of
Directors. Mr. Parker brings over 30 years of finance and
executive leadership experience to the Board including, most
recently, serving as Executive Vice President and Chief Financial
Officer of Anacor Pharmaceuticals, Inc., which he joined in 2010 at
the time of its initial public offering. Sunesis also
announced that Helen Kim stepped down from her position as a
Director.
“Geoff’s extensive experience in healthcare
finance and operations will be invaluable to Sunesis,” said Daniel
Swisher, Chief Executive Officer of Sunesis. “We welcome Geoff to
our Board and look forward to his strategic counsel as we work
towards achieving our future corporate objectives including in 2016
moving vosaroxin through the regulatory approval process in Europe,
entering into an ex-US partnership and advancing our kinase
inhibitor pipeline to meaningful data milestones. At the same time,
we would like to thank Helen Kim for her significant contributions
as a Director.”
“I am delighted to be joining Sunesis as a Board
Member,” stated Mr. Parker. “Sunesis is at a pivotal point in its
evolution with a broad pipeline of differentiated cancer
therapeutics and an experienced management team and Board of
Directors. I look forward to contributing to the achievement of its
strategic plan and supporting Sunesis’ future growth.”
During his five years at Anacor from 2010 to
2015, Mr. Parker helped lead the company during the FDA approval
and commercial launch of KERYDIN® (tavaborole) and was
instrumental in securing partnerships and financing the company’s
product pipeline. Prior to Anacor, Mr. Parker had significant
transactional and advisory experience working with life sciences
companies in various capacities at Goldman Sachs, leading the
firm’s West Coast Healthcare Investment Banking practice for twelve
years.
Mr. Parker currently serves as a member of the
Board of Directors of ChemoCentryx, Inc. He received an A.B.
from Dartmouth College in Engineering Sciences and Economics and an
M.B.A. from the Stanford Graduate School of Business.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic
cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people
with cancer and is currently pursuing regulatory approval
in Europe for its lead product candidate, vosaroxin, for
the treatment of relapsed or refractory acute myeloid leukemia in
patients aged 60 and older. In addition, the company is advancing
its kinase-inhibitor pipeline of novel targeted therapies into the
clinic.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to Sunesis' corporate
objectives, including the anticipated progress and potential
approval of vosaroxin by the EMA, potential ex-US partnership, and
the expected progress in its kinase inhibitor pipeline. Words such
as “look forward,” "potential," "will" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Sunesis' current
expectations. Forward-looking statements involve risks and
uncertainties. Sunesis' actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risk that
Sunesis may not be able to receive regulatory approval of vosaroxin
in the U.S. or Europe, that Sunesis' development activities
for vosaroxin could be otherwise halted or significantly delayed
for various reasons, the risk that Sunesis' clinical studies for
vosaroxin or other product candidates, including its pipeline of
kinase inhibitors, may not demonstrate safety or efficacy or lead
to regulatory approval, the risk that data to date and trends may
not be predictive of future data or results, risks related to the
conduct of Sunesis' clinical trials, risks related to Sunesis' need
for substantial additional funding to complete the development and
commercialization of vosaroxin and other product candidates, and
risks related to Sunesis' ability to raise the capital that it
believes to be accessible and is required to fully finance the
development and commercialization of vosaroxin and other product
candidates. These and other risk factors are discussed under "Risk
Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for
the year ended December 31, 2015 and Sunesis' other filings
with the Securities and Exchange
Commission. Sunesis expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Sunesis' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024